Sigachi Laboratories Limited Balance Sheet(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
EQUITY AND LIABILITIES
|
42.66 |
40.91 |
37.34 |
31.26 |
30.28 |
|
Total equity
|
40.88 |
39.33 |
36.01 |
30.74 |
29.75 |
|
Total liabilities
|
1.78 |
1.59 |
1.34 |
0.52 |
0.53 |
|
Non - Current liabilities
|
1.66 |
1.49 |
1.26 |
0.43 |
0.47 |
|
Current liabilities
|
0.12 |
0.10 |
0.08 |
0.09 |
0.07 |
|
ASSETS
|
42.66 |
40.91 |
37.34 |
31.26 |
30.28 |
|
Non-Current assets
|
38.42 |
37.18 |
34.47 |
25.23 |
26.70 |
|
Current assets
|
4.24 |
3.74 |
2.87 |
6.03 |
3.58 |
Sigachi Laboratories Limited CashFlow Statement(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
Net cash from/(used in) operating activities
|
1.56 |
0.52 |
-1.90 |
0.48 |
-2.16 |
|
Net cash from/(used in) investing activities
|
-3.09 |
0.90 |
-1.36 |
2.43 |
0.54 |
|
Net cash from/(used) in financing activities
|
0.00 |
|
|
|
|
|
Net increase /(decrease) in cash and cash equivalents
|
-1.53 |
1.42 |
-3.27 |
2.91 |
-1.62 |
|
Cash and cash equivalents at the beginning of the year
|
1.86 |
0.45 |
3.71 |
0.81 |
2.43 |
|
Cash and cash equivalents at the end of the year
|
0.33 |
1.86 |
0.45 |
3.71 |
0.81 |
Sigachi Laboratories Limited Finacial Ratios(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
EBITDA Margin
|
51.73% |
46.38% |
69.75% |
78.43% |
83.68% |
|
EBIT Margin
|
45.24% |
40.25% |
64.58% |
70.72% |
78.15% |
|
Return on Equity (ROE)
|
3.28% |
3.03% |
5.48% |
4.26% |
6.71% |
|
Return on Capital Employed (ROCE)
|
4.26% |
3.73% |
7.56% |
5.56% |
7.86% |
|
Assets Turnover Ratio
|
0.09 |
0.09 |
0.12 |
0.08 |
0.10 |
|
Return on Assets
|
3.14% |
2.91% |
5.29% |
4.19% |
6.59% |
|
Net Profit Margin
|
33.44% |
31.49% |
45.29% |
53.48% |
65.72% |
|
Revenue Growth Rate (CAGR)
|
5.90% |
-13.26% |
77.99% |
-19.36% |
-21.10% |
Sigachi Laboratories Limited Income Statement(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
Revenue
|
4.00 |
3.78 |
4.36 |
2.45 |
3.04 |
|
Revenue from operations
|
3.26 |
3.12 |
3.74 |
1.95 |
2.60 |
|
Other income
|
0.75 |
0.66 |
0.62 |
0.50 |
0.44 |
|
Expenses
|
2.20 |
2.26 |
1.54 |
0.72 |
0.66 |
|
Finance cost
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
Employee benefit Expense
|
0.47 |
0.43 |
0.39 |
0.36 |
0.34 |
|
Depreciation and Amortisation expense
|
0.26 |
0.23 |
0.23 |
0.19 |
0.17 |
|
Other expenses
|
0.17 |
1.60 |
0.93 |
0.17 |
0.15 |
|
Profit/(loss) before tax
|
1.81 |
1.52 |
2.82 |
1.73 |
2.37 |
|
Tax Expense
|
0.47 |
0.33 |
0.84 |
0.42 |
0.38 |
|
Current tax
|
0.55 |
0.46 |
0.41 |
0.46 |
0.40 |
|
Deferred tax
|
-0.08 |
-0.12 |
0.43 |
-0.04 |
-0.02 |
|
Profit (Loss) for the period from continuing Operations
|
1.34 |
1.19 |
1.97 |
1.31 |
2.00 |
Sigachi Laboratories Limited Summary(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
Revenue
|
4.00 |
3.78 |
4.36 |
2.45 |
3.04 |
|
Total Expense
|
2.20 |
2.26 |
1.54 |
0.72 |
0.66 |
|
Operating Expenses
|
0.90 |
2.26 |
1.54 |
0.72 |
0.66 |
|
Employee Expenses
|
0.47 |
0.43 |
0.39 |
0.36 |
0.34 |
|
Operating Income (EBIT)
|
1.81 |
1.52 |
2.82 |
1.73 |
2.37 |
|
Interest Expenses
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
Expenses from other activities
|
0.17 |
1.60 |
0.93 |
0.17 |
0.15 |
|
EBITDA
|
2.07 |
1.75 |
3.04 |
1.92 |
2.54 |
|
Net Worth
|
40.88 |
39.33 |
36.01 |
30.74 |
29.75 |
|
Taxes
|
0.47 |
0.33 |
0.84 |
0.42 |
0.38 |
|
Outstanding Shares
|
6,753,100.00 |
6,753,100.00 |
6,753,100.00 |
6,753,100.00 |
6,753,100.00 |
|
Earnings Per Share (EPS)
|
1.98 |
1.76 |
2.92 |
1.94 |
2.96 |
|
Total Assets
|
42.66 |
40.91 |
37.34 |
31.26 |
30.28 |
|
Total Liabilites
|
1.78 |
1.59 |
1.34 |
0.52 |
0.53 |
|
Total equity
|
40.88 |
39.33 |
36.01 |
30.74 |
29.75 |
|
Net cash from/(used in) operating activities
|
1.56 |
0.52 |
-1.90 |
0.48 |
-2.16 |
|
Net cash from/(used in) investing activities
|
-3.09 |
0.90 |
-1.36 |
2.43 |
0.54 |
|
Net cash from/(used) in financing activities
|
0.00 |
|
|
|
|
